Top growth stocks ASX 2026

The following three ASX growth stocks look like solid picks right now because they continue to generate high returns on capital through strong competitive advantages which is difficult for competitors to replicate.

Top growth stocks ASX

Catapult Sports Limited (ASX: CAT) 

REA Group Limited (ASX: REA) 

Pro Medicus Limited (ASX: PME) 

Catapult Sports Limited (ASX: CAT) 

is one of the top ASX growth stocks right now and current market capitalisation is $982.73 million. It is a global leader in sports performance analytics and athlete monitoring technology.
The company in 1H FY26 reported strong operational momentum as Annualised Contract Value (ACV) grew 19% while Management EBITDA margin increased to 14%.

Its large proprietary dataset which has been built over more than 15 years, contains billions of data points from athlete performance and video analysis which gives the company a strong competitive advantage because it is difficult for competitors to replicate.
Higher solution penetration along with broader use cases also supports the strength and scalability of the company’s core business model.

Catapult Sports plans to execute its “land and expand” strategy which targets scaling Annualized Contract Value (ACV) towards more than US$1 billion over the medium- term.

Management is targeting contribution margins of around 55% and management EBITDA margins of around 30% while the financial results for the year ended March 31 2026 will be released on May 20 2026 which should provide further clarity on the company’s future.

REA Group Limited (ASX: REA) 

is one of the top ASX growth stocks with a market capitalisation of approximately $21.8 billion and the company has shown strong operational and financial performance across its property technology ecosystem.

The company in Q3 FY26 reported an excellent result as revenue rose 11% excluding M&A activity to $398 million while operating EBITDA increased 16% to $220 million and free cash flow improved to $135 million compared with the prior corresponding period.
User engagement also reached record levels with 12.9 million average monthly users and 150 million monthly visits while active members increased 19%.

Recent developments improved the long-term outlook because REA expanded its AI powered conversational search tools launched iGUIDE Australia operations and further grew its financial services ecosystem through Mortgage Choice and PropTrack.

Management is optimistic as the company expects approximately 13% residential Buy yield growth in FY26 while positive operating leverage and ongoing product innovation continue to support sustained long-term earnings growth.

Pro Medicus Limited (ASX: PME) 

is one of the top ASX growth stocks with a market capitalisation of $12.74 billion and the stock is now at undervalued levels as it has declined nearly 55% in the past 12 months.

The company on 8 April 2026 signed a 5-year $23 million contract with the University of Maryland Medical System which will introduce its cloud-based Visage 7 platform across the entire network.
Management stated that nearly $80 million in renewals were secured within one month which highlights strong customer retention along with significant pricing power.

The company in HY26 reported strong financial performance as revenue increased 28.4% year-on-year to $124.8 million which reflects solid growth compared to the prior corresponding period.

Profit after tax reached $171.2 million after rising 230.9% year-on-year while the balance sheet is very healthy with cash and investments of $221.8 million and the company is debt free.

(Source: Company Reports)